Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse eventsMarie Kostine, Thierry Schaeverbeke, M. Beylot‐Barry et al.|European Journal of Cancer|2021Cited by 93
Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysisCéline Eldani, E. Gérard, M. Beylot‐Barry et al.|Frontiers in Oncology|2024Cited by 14
OP0336 COMMONLY USED DRUGS IN RHEUMATOLOGY MAY ALTER ANTI-TUMORAL RESPONSE TO IMMUNE CHECKPOINT INHIBITORSMarie Kostine, Thierry Schaeverbeke, Baptiste Sionneau et al.|Annals of the Rheumatic Diseases|2019Cited by 1